Free Trial
NASDAQ:XCUR

Exicure (XCUR) Stock Price, News & Analysis

Exicure logo
$10.34 -0.11 (-1.05%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Exicure Stock (NASDAQ:XCUR)

Key Stats

Today's Range
$10.00
$10.25
50-Day Range
$7.61
$14.28
52-Week Range
$1.44
$36.00
Volume
2,110 shs
Average Volume
569,471 shs
Market Capitalization
$65.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Exicure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

XCUR MarketRank™: 

Exicure scored higher than 44% of companies evaluated by MarketBeat, and ranked 834th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Exicure.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exicure is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exicure is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exicure has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exicure's valuation and earnings.
  • Percentage of Shares Shorted

    3.34% of the float of Exicure has been sold short.
  • Short Interest Ratio / Days to Cover

    Exicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exicure has recently decreased by 19.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exicure does not currently pay a dividend.

  • Dividend Growth

    Exicure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.34% of the float of Exicure has been sold short.
  • Short Interest Ratio / Days to Cover

    Exicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exicure has recently decreased by 19.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Exicure has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Exicure this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for XCUR on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Exicure to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exicure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Exicure is held by insiders.

  • Percentage Held by Institutions

    42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exicure's insider trading history.
Receive XCUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter.

XCUR Stock News Headlines

The collapse has already started
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
See More Headlines

XCUR Stock Analysis - Frequently Asked Questions

Exicure's stock was trading at $13.67 at the beginning of 2025. Since then, XCUR shares have decreased by 24.4% and is now trading at $10.34.
View the best growth stocks for 2025 here
.

Exicure, Inc. (NASDAQ:XCUR) released its earnings results on Tuesday, March, 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.

Exicure shares reverse split before market open on Tuesday, August 27th 2024. The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET).

Company Calendar

Last Earnings
3/18/2025
Today
5/01/2025
Next Earnings (Estimated)
6/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XCUR
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,910,000.00
Pretax Margin
-799.80%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.97

Miscellaneous

Free Float
2,504,000
Market Cap
$66.02 million
Optionable
Not Optionable
Beta
3.74
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:XCUR) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners